Literature DB >> 26484401

Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.

Colin Rae1, Uwe Haberkorn2, John W Babich3, Robert J Mairs1.   

Abstract

Many common human cancers, including colon, prostate and breast cancer, express high levels of fatty acid synthase compared to normal human tissues. This elevated expression is associated with protection against apoptosis, increased metastasis and poor prognosis. Inhibitors of fatty acid synthase, such as the cerulenin synthetic analog C75, decrease prostate cancer cell proliferation, increase apoptosis and decrease tumor growth in experimental models. Although radiotherapy is widely used in the treatment of prostate cancer patients, the risk of damage to neighboring normal organs limits the radiation dose that can be delivered. In this study, we examined the potential of fatty acid synthase inhibition to sensitize prostate cancer cells to radiotherapy. The efficacy of C75 alone or in combination with X irradiation was examined in monolayers and in multicellular tumor spheroids. Treatment with C75 alone decreased clonogenic survival, an effect that was abrogated by the antioxidant. C75 treatment also delayed spheroid growth in a concentration-dependent manner. The radiosensitizing effect of C75 was indicated by combination index values between 0.65 and 0.71 and the reduced surviving fraction of clonogens, in response to 2 Gy X irradiation, from 0.51 to 0.30 and 0.11 in the presence of 25 and 35 μM C75, respectively. This increased sensitivity to radiation was reduced by the presence of the antioxidant. The C75 treatment also enhanced the spheroid growth delay induced by X irradiation in a supra-additive manner. The level of radiation-induced apoptosis in prostate cancer cells was increased further by C75, which induced cell cycle arrest in the G2/M phase, but only at a concentration greater than that required for radiosensitization. Radiation-induced G2/M blockade was not affected by C75 treatment. These results suggest the potential use of fatty acid synthase inhibition to enhance the efficacy of radiotherapy of prostate carcinoma and that C75-dependent cell cycle arrest is not responsible for its radiosensitizing effect.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26484401     DOI: 10.1667/RR14173.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  18 in total

1.  Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.

Authors:  Joshua J Souchek; Amanda L Davis; Tanner K Hill; Megan B Holmes; Bowen Qi; Pankaj K Singh; Steven J Kridel; Aaron M Mohs
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

2.  Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.

Authors:  Jordan O'Malley; Rahul Kumar; Andrey N Kuzmin; Artem Pliss; Neelu Yadav; Srimmitha Balachandar; Jianmin Wang; Kristopher Attwood; Paras N Prasad; Dhyan Chandra
Journal:  Cancer Lett       Date:  2017-03-23       Impact factor: 8.679

Review 3.  Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Authors:  Yong Weon Yi; Kyu Sic You; Jeong-Soo Park; Seok-Geun Lee; Yeon-Sun Seong
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

4.  Enhancing 223Ra Treatment Efficacy by Anti-β1 Integrin Targeting.

Authors:  Claudia Paindelli; Stefano Casarin; Feng Wang; Luis Diaz-Gomez; Jianhua Zhang; Antonios G Mikos; Christopher J Logothetis; Peter Friedl; Eleonora Dondossola
Journal:  J Nucl Med       Date:  2021-10-28       Impact factor: 11.082

5.  Patuletin induces apoptosis of human breast cancer SK-BR-3 cell line via inhibiting fatty acid synthase gene expression and activity.

Authors:  Wanwan Zhu; Chunmei Lv; Jiao Wang; Qiang Gao; Hui Zhu; Haixia Wen
Journal:  Oncol Lett       Date:  2017-10-09       Impact factor: 2.967

6.  Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.

Authors:  Yeu-Sheng Tyan; Yen-Po Lee; Hui-Yen Chuang; Wei-Hsun Wang; Jeng-Jong Hwang
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

7.  Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells.

Authors:  Donna L Nile; Colin Rae; David J Walker; Joe Canning Waddington; Isabel Vincent; Karl Burgess; Mark N Gaze; Robert J Mairs; Anthony J Chalmers
Journal:  Cancer Metab       Date:  2021-05-19

8.  Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells.

Authors:  N McDermott; A Meunier; B Mooney; G Nortey; C Hernandez; S Hurley; N Lynam-Lennon; S H Barsoom; K J Bowman; B Marples; G D D Jones; L Marignol
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

9.  Differential in radiosensitizing potency of enantiomers of the fatty acid synthase inhibitor C75.

Authors:  Colin Rae; John W Babich; Robert J Mairs
Journal:  Chirality       Date:  2016-11-30       Impact factor: 2.437

10.  Comparison of gene expression in liver regeneration and hepatocellular carcinoma formation.

Authors:  Li Yin; Yahao Wang; Xueqiang Guo; Cunshuan Xu; Guoying Yu
Journal:  Cancer Manag Res       Date:  2018-11-15       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.